• 대한핵의학회지
• /
• 제27권2호
• /
• pp.261-269
• /
• 1993

핵의학 분야에 사용되는 항체의 적절한 동위원소 표지법을 선택하는데는 표지항체의 면역반응성을 평가하는 것이 매우 중요한 일이다. 저자 등은 국내에서 개발된 CEA-79 단세포군 항체를 표지방법 및 비방사능을 $0.1{\mu}Ci/{\mu}g$으로부터 $100{\mu}Ci/{\mu}g$까지 달리하여 $^{125}I$ 표지를 시행한 후 면역반응성을 평가하고, 이 항체에 적절한 표지방법을 찾고자 하였다. 면역반응성의 평가에 있어서는 표지, 비표지 항체의 경쟁반응을 이용하여 표지항체의 비표지항체에 대한 상대적 면역반응성을 평가하는 새로운 방법을 시도해 보았다. 그 결과 CEA-79 항체의 강우, chlormine T법이 iodogen법보다 우수하였는데, 즉, chloramine T법으로 표지시에는 비방사능을 $100{\mu}Ci/{\mu}g$까지 높여도 면역반응성이 잘 유지되고 시간경과에 따른 면역반응성의 변화도 적었다. 본 연구에서 시도한 새로운 경쟁반응방법은 동위원소표지에 의한 항체의 면역반응성의 손상을 평가하는데 효과적이었으며, 기존의 세포결합 검사법보다 간편하였다. 또 항체의 면역반응성은 비방사능과 함께 방사면역계수법의 민감도에 영향을 미침을 확인할 수 있었다. 따라서 표지항체의 면역반응성과 비방사능은 그 용도에 따라 적정화되어야 할 것이며, 본 연구에서 시도한 경쟁반응방법은 적정한 동위원소 표지 방법을 선택하는데 유용할 것으로 사료된다.

• 한국원자력학회:학술대회논문집
• /
• 한국원자력학회 2005년도 춘계학술발표회
• /
• pp.938-939
• /
• 2005

• 대한핵의학회지
• /
• 제15권2호
• /
• pp.35-41
• /
• 1981

The radioimmunoassay of human thyrtropin was performed in various thyroid diseases, using the antin-h-TSH antibody (Daiichi, Japan) and purified h-TSH(Biodata, Italy). $^{125}I$ labelling of h-TSH was performed using a small amount $(1.8{\mu}g)$ of chloramin-T as an oxidant at room temperature. This new method facilitated uniform labelling and reduced to damage of h-TSH by chloramin-T, and satisfactory radioimmunoasasy results were obtained with $^{125}I-TSH$ prepared by the new method until at least 7 weeks after preparation, The assay sensitivity was $1.0{\mu}u/ml$. The coefficient of variances in within assay and interrun assay were all less than 10% among the range of $1.25{\mu}u/ml$ and $160{\mu}u/ml$. The serum TSH values by this new method were colsely related to those by commercial kit (r= 0.996).

• 대한핵의학회지
• /
• 제15권2호
• /
• pp.27-33
• /
• 1981

Human thyrotropin(h-TSH)의 $^{125}I$-표지를 실온서 소량의 Chloramine T를 산화제로 사용하여 수행하였다. 이 방법은 다량의 Chloramine T를 사용하는 종래의 방법과 비교하여 균일한 방사능 표지를 용이하게 하고 강력한 산화제인 Chloramine T에 의한 h-TSH의 파손을 줄여 주었다. 새로운 방법에 의해 합성된 $h-TSH^*$는 항체에 대한 친화도와 유효기간에 있어서 Daiichi 회사의 상품에 비교하여 손색이 없었다.

• 대한핵의학회지
• /
• 제31권4호
• /
• pp.440-451
• /
• 1997

본 연구에서는 항암제인 taxol의 $^{111}In$ 방사성표지화합물을 합성하여 암진단제로서의 이용 가능성을 보기 위한 기초 연구를 수행하였다. Taxol의 $^{111}In$ 표지화합물을 얻기 위해 taxol구조에서 C-13의 곁가지에 있는 C-2' 부분의 hydroxyl기를 DTPA anhydride 및 succinic anhydride와 반응시켜 taxol-DTPA와 2'-hemisuccinyltaxol을 합성하였다. 반응수율은 taxol-DTPA 접합체의 경우 34%이었으며, 2'-hemisuccinyltaxol은 80%이었다. MTT법을 사용하여 HT29, B16, P388, CT26 세포주에서 taxol-DTPA와 2'-hemisuccinyltaxol의 세포독성능실험에서는 taxol 보다는 못미치나 그 세포독성이 유지됨을 확인하였다. 합성된 taxol 유도체들을 리간드 교환법과 직접법을 사용하여 In-111을 표지하였다. Taxol-DTPA 접합체의 In-111 표지반응의 경우, 리간드교환법은 반응도중 침전이 생겨 반응이 어려워 직접법으로 In-111 표지화합물을 얻을 수 있었으며 그 표지수율은 100%이었다. 2'-hemisuccinyltaxol은 두 방법을 모두 시도하였으나 반응이 진행되지 않음을 확인하였다. In-111의 taxol-DTPA 접합체 및 2'-hemisuccinyltaxol에 대한 표지반응 수율은 HPLC, paper, instant thin-layer chromatography를 실시하여 결정하였다. Li-pophilicity의 실험에서는 친수성임이 확인되었으며, 세포결합능의 실험에서는 HT29, B16, P388, CT26 세포주와의 결합이 매우 낮음을 나타내었다. 혈청단백 질과의 결합능을 보기위하여 30% trichloroacetic acid 법을 수행하였으며, 약 30%정도만이 혈청단백질과 결합하여 그 값이 크지 않았다.

• 한국식품과학회지
• /
• 제22권7호
• /
• pp.774-779
• /
• 1990

치즈 제조시 열처리와 한외거르기를 통하여 생산량이 증가되는 정도를 방사성 동위원소 $[^{14}C]$가 표지된 락토글로불린을 이용하여 분석하였다. 그 결과 열처리를 통하여 4.33%의 ${\beta}$-락토글로불린이 치즈 커드에 결합되었으며, 한외거르기를 통하여 $3.20{\sim}6.65%$의 ${\beta}$-락토글로불린이 생산량 증대에 관여하였다. 단백질의 증가와 비교해 본 결과, 다른 유청단백질도 한외거르기, 열처리 효과에 의하여 치즈 커드와 결합하는 것으로 추측되었으며 한외거르기시 막에 흡착되거나 하여 손실된 양은 1.03% 이었다.

• 대한방사성의약품학회지
• /
• 제2권1호
• /
• pp.43-50
• /
• 2016

$^{89}Zr$ with the favorable nuclear decay kinetics and chemical properties is an appealing radiometal for its application in immuno-PET using radiolabeled monoclonal antibodies. Rising demand of ultrahigh purity and high-specific activity $^{89}Zr$ has propelled the radiochemist worldwide to develop an overall efficacious method for its promising separation from the target matrix $^{89}Y$. The requirement of elevated radiochemical purity (${\geq}$ 99.99%) has accelerated the efforts since last two decades to achieve higher decontamination and separation factors of carrier free $^{89}Zr$ over $^{89}Y$ using several suitable separation techniques. However, each of the technique has its own pros and cons which prior to its actual medical application needs to be optimized and thoroughly scrutinized to avoid further complications during radiolabelling of the pharmaceuticals. In this short review article we will specifically consider as well focus on the historical development and the recent advances on the radiochemical separation of $^{89}Zr$ from $^{89}Y$ which will be helpful for the separation scientist involved in this area to understand the existing available means and plan the strategy to investigate and develop the novel techniques to overcome the problems involved in the present methods.

• 대한바이러스학회지
• /
• 제28권1호
• /
• pp.53-62
• /
• 1998

Human papillomavirus (HPV) 16, E7 proteins derived from the prototype (Bac73) and natural variant (Bac101) E7 open reading frame were produced in Sf9 insect cells. The variant E7 gene occurred naturally by substitution mutation at the position of 88 nucleotide, resulting serine instead of asparagine. Using E7 specific monoclonal antibody (VD6), both E7 proteins were identified in recombinant baculovirus infected SF9 cells. Radiolabelling and immunoprecipitation analysis revealed that both E7 proteins were phosphoproteins. Immunostaining result showed that E7 proteins were mainly localized in the cytoplasm. Nuclear form of E7 proteins was also detected after a sequential fractionation procedure for removing chromatin structure. Considering that the VD6 recognition site in E7 protein is located within 10 amino acid at the N-terminus, this region appears to be blocked by the nuclear component. Western blot analysis revealed that nuclear form was more abundant than cytoplasmic E7 proteins. Time course immunostaining showed that the primary location of E7 protein was the nucleus and exported to the cytoplasm as proteins were accumulated. These events occurred similarly in both Bac73 and Bac101 infected Sf9 cells, suggesting that these two proteins may have similar biological functions.

• 방사선산업학회지
• /
• 제9권4호
• /
• pp.193-198
• /
• 2015

Most of targeted therapies block the action of certain enzymes, proteins, or other molecules involved in the growth and spread of cancer cells to produce its cytotoxic effect. Either small molecule drugs or monoclonal antibodies are mostly used in targeted therapies. Unfortunately, targeted therapy has a certain degree of unwanted side effect like other cytotoxicity inducing chemotherapies. To overcome and to reduce unwanted side effects during a cancer therapy, recently radiopeptide therapies has got the worlds' attraction for the tumor targeting modalities due to its beneficial effect on less side effect compared to cytotoxic chemotherapies. Among radiopeptide therapies, $^{177}Lu$-DOTATATE is a major modality as an effective one invented so far in treating neuroendocrine tumor (NET) and it has been in clinical trials at least one decade. Although it does have rather effective therapeutic effect on NET, it has less effective in rather large solid tumor. There are many ways to improve or increase therapeutic effect of radiopeptide are a finding the potent small molecules to target the tumor site selectively, or a labeling with radioisotope of emitting high energy, or an improving its biological half-life by introducing different moieties to increase lipophilicity. Present study was focus to increase a biological half-life of radio somatostatin which will target the somatostatin receptor by altering the bifunctional chelator (BFCA) by introducing lipophilic moiety to the somatostatin, which would make the labeled peptide stay longer in the tumor site and thus it can intensify the therapeutic effect on tumor cell itself and around tissues.

• 대한방사성의약품학회지
• /
• 제4권2호
• /
• pp.65-72
• /
• 2018

Prostate specific membrane antigen (PSMA) is a cell surface membrane protein, which is overexpressed in most prostate cancer. Recently, PET imaging with $[^{68}Ga]$PSMA-HBED-CC has been widely used for the diagnosis of recurrent prostate cancer and the studies on the diagnostic potential of $^{64}Cu$-labeled PSMA ligands reported actively. In this study, we monitored with biological evaluation in vivo and PET imaging of $^{64}Cu$-labeled PSMA ligand ($[^{64}Cu]$PSMA-617). The radiolabelling efficiency and stability of $[^{64}Cu]$PSMA-617 were confirmed by radio-thin layer chromatography. The radiolabeling efficiency of $[^{64}Cu]$PSMA-617 showed over 95%, and stabilities of intact remained over 98% in both human and mouse serum for 48 h. In normal male mice, in vivo uptake of $[^{64}Cu]$PSMA-617 in several organs was measured at 2, 4, 6, 24, 48 h after injection. Rapid blood clearance was observed for $[^{64}Cu]$PSMA-617. The high uptake was observed in the lung, liver, intestines and kidneys at 2 h postinjection, but was low in the other organs (1-2 %ID/g) at 4 h. The dynamic PET/CT images of 22RV1 tumor-bearing nude mice were acquired during 60 min and additionally acquired 24 h and 48 h after injection. In dynamic PET images, $[^{64}Cu]$PSMA-617 uptake ratio in tumors versus muscle was increased as time elaplsed until 60 minutes and remained in tumors at 48 h. In these results, the PET/CT imaging using $[^{64}Cu]$PSMA-617 in prostate cancer is expected to be useful for the diagnosis and treatment of prostate cancer patients.